Word: grouped
(lookup in dictionary)
(lookup stats)
Dates: during 1990-1999
Sort By: most recent first
(reverse)
...game of averages, and Davis certainly doesn't bat .1000; Puff Daddy's solo album Forever is off to a slow start. But Arista has created enough hits to help lift the market share of its corporate parent BMG from 14% to 18%, second only to the Universal Music Group...
...everyone has believed in Davis' ears. He launched Arista only after being canned by Columbia Records in 1973. By the 1980s, the former lawyer was tasting major success with a diverse group of performers, including Barry Manilow and the Grateful Dead. BMG purchased Arista in 1979, but Davis still operates virtually independently, unusual in an era when big corporations rule music. That might be because he has served the bean counters well too, finding efficient ways to achieve growth. Instead of shelling out millions for outright acquisitions of artists or their production companies, Davis puts money into joint ventures...
...M.I.T. and IBM are preparing for a world in which every transaction becomes a complex trade deal between a pricing bot acting for the site and a shopping bot acting for you. "Dynamic pricing, that's the big notion," says Professor Pattie Maes, director of the software-agents group at the M.I.T. media lab. "After all, fixed prices have been around only for a couple of hundred years...
This bot-driven universe won't arrive until a few kinks have been ironed out. Right now, says Jeff Kephart, manager of the agents and e-merchant phenomena group at IBM, price bots don't understand that undercutting your competitor is not always smart. "This gives rise to price wars," says Kephart, who in tests has watched the sell bots give the store away in a competitive frenzy. "They're pretty dumb," he notes. "We have to give them a sense of anticipation...
...company finally began testing FGN-1 on humans. In a trial of 18 patients with FAP, 12 showed substantial improvement. One patient, who was developing about 100 polyps a year, had no polyps at all while on the drug. This led to another, larger double-blind study with one group taking a placebo, the other FGN-1. But midway it was discovered that the recruitment of patients had been mishandled and a year's worth of work was lost. Still, Nichols could see that in a core group of subjects the drug was working as he had hoped...